Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Novartis announced that the Committee for Medicinal Products ... Data from the pivotal trial also showed the safety profile of Kisqali at the 400mg dose was well-tolerated with generally low-grade ...

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

Also Read: Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term ... trial also showed that the safety profile of Kisqali at the 400mg dose was well-tolerated, with generally low ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

EAST HANOVER, N.J., Oct. 18, 2024 /PRNewswire/ -- Novartis announced today that ... trial also showed the safety profile of Kisqali at the 400mg dose was well-tolerated with generally low-grade ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis NVS announced that the Committee ... Data from the pivotal trial also showed that Kisqali's safety profile at the 400mg dose was well-tolerated, with generally low-grade symptomatic ...

If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy," said Patrick Horber M.D., President, International, Novartis. "Together with the ...

If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy," said Patrick Horber M.D., President, International, Novartis. "Together with the recent ...

Data from the pivotal trial also showed the safety profile of Kisqali at the 400mg dose was well-tolerated ... International, Novartis. "Together with the recent FDA approval and late-breaking ...